Zobrazeno 1 - 10
of 47
pro vyhledávání: '"C Muñoz Villafranca"'
Autor:
M Chaparro, M García Donday, S Riestra, A J Lucendo, J M Benítez, M Navarro-Llavat, J Barrio, V J Morales-Alvarado, M Rivero, D Busquets, E Leo Carnerero, O Merino Ochoa, O Nantes Castillejo, P Navarro, M Van Domselaar, A Gutiérrez Casbas, I Alonso-Abreu, R Mejuto, L Fernández Salazar, M Iborra, M D Martín-Arranz, J R Pineda, M J Sampedro, K Serra Nilsson, A Bouhmidi Assakali, L Batista, C Muñoz Villafranca, I Rodríguez-Lago, D S Ceballos Santos, I Guerra, M Mañosa, I Marín Jimenez, I Vera Mendoza, M Barreiro-de Acosta, E Domènech, M Esteve, V García-Sánchez, P Nos, J Panés, J P Gisbert
Publikováno v:
Journal of Crohn's and Colitis. 17:i50-i54
Background Background: The feasibility of anti-TNF discontinuation in inflammatory bowel disease (IBD) must be proven in clinical trials including patients in clinical, endoscopic, and radiologic remission at the time of anti-TNF withdrawal to make r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8acd9ed996ae8e4fcd0df9c8a1758fb8
https://doi.org/10.1093/ecco-jcc/jjac190.0037
https://doi.org/10.1093/ecco-jcc/jjac190.0037
Autor:
M Chaparro, D Acosta, C Rodríguez, F Mesonero, M Vicuña, M Barreiro-de Acosta, A Fernández-Clotet, Á Hernández Martínez, M Arroyo, I Vera, A Ruiz-Cerulla, B Sicilia, M J Cabello Tapia, C Muñoz Villafranca, J Castro-Poceiro, J Martínez Cadilla, M Sierra-Ausín, J M Vázquez Morón, E Montil Miguel, F Bermejo, V Royo, M Calafat, C González-Muñoza, E Leo Carnerero, N Manceñido Marcos, L Torrealba, H Alonso-Galán, J M Benítez, Y Ber Nieto, M T Diz-Lois Palomares, M J García, J F Muñoz, E M Armesto González, X Calvet, A Hernández-Camba, R E Madrigal Domínguez, L Menchén, J L Pérez Calle, M Piqueras, J P Gisbert
Publikováno v:
Journal of Crohn's and Colitis. 17:i806-i808
Background Main aim: To assess the durability of tofacitinib treatment in patients with ulcerative colitis (UC). Secondary aims: To assess the short and long-term effectiveness; the tolerability of tofacitinib in clinical practice; and to evaluate th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::592845492cf6ce9454ce40638b4aaa99
https://doi.org/10.1093/ecco-jcc/jjac190.0805
https://doi.org/10.1093/ecco-jcc/jjac190.0805
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
M Chaparro, D Acosta, C Rodríguez, M Vicuña, F Mesonero, M Barreiro-de Acosta, A Fernández-Clotet, Á Hernández Martínez, M T Arroyo, I Vera Mendoza, B Sicilia, C Muñoz Villafranca, J Castro-Poceiro, J Martínez Cadilla, J M Vázquez Morón, E Montil, M Sierra-Ausín, M Calafat, E Leo Carnerero, N Manceñido Marcos, L Torrealba M, H Alonso-Galán, J M Benítez, Y Ber Nieto, M J Cabello Tapia, M T Diz-Lois Palomares, M J García, E M Armesto González, X Calvet Calvo, M Piqueras, C Dueñas Sadornil, J L Pérez Calle, B Botella, T D J Martínez-Pérez, L Ramos, M C Rodríguez-Grau, J L Fernández Forcelledo, A Gutiérrez, E Sesé Abizanda, J P Gisbert
Publikováno v:
Journal of Crohn's and Colitis. 16:i375-i377
Background Main aim: To assess the retention rate of tofacitinib treatment in patients with ulcerative colitis (UC). Secondary aims: To assess the short-term effectiveness and the durability of response; to evaluate the evolution of extraintestinal m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9c2067054ede194b5d2e0f136d83543d
https://doi.org/10.1093/ecco-jcc/jjab232.500
https://doi.org/10.1093/ecco-jcc/jjab232.500
Autor:
C Muñoz-Villafranca, P Arreba, M Gomez, N Ispizua Madariaga, L Buendia, M L Lopez, A Ugarte, I de la Fuente, N Prado, L Irusta, M A Jimenez, M Santa Cruz, M Gonzalez, A Bilbao, J Ortiz de Zárate
Publikováno v:
Journal of Crohn's and Colitis. 17:i723-i723
Background The usefulness of therapeutic drug monitoring(TDM) of infliximab during induction and its relationship with clinical outcome in patients with inflammatory bowel disease(IBD) is well established. However, the optimal time of monitoring in t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e9eec203693ae500a5963e38ca6b1b4f
https://doi.org/10.1093/ecco-jcc/jjac190.0725
https://doi.org/10.1093/ecco-jcc/jjac190.0725
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Jone Ortiz de Zarate, C Muñoz-Villafranca, Martin Irabien, Nahia Ispizua-Madariaga, Saioa de la Maza-Ortiz, Paz Arreba, Nerea Hernandez-Aretxabaleta
Publikováno v:
Revista Española de Enfermedades Digestivas.
Toxic megacolon is most commonly considered as a complication of inflammatory bowel disease, especially ulcerative colitis and colonic Crohn’s disease to a lesser extent. It appears in the context of moderate-to-severe disease and often requires co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ee1bad3a718dcb67428732cdcea22c5a
https://doi.org/10.17235/reed.2020.7228/2020
https://doi.org/10.17235/reed.2020.7228/2020
Autor:
E Sainz, B Herreros, Luis Fernández-Salazar, Pedro Zapater, Blau Camps, Y Zabana, Beatriz Sicilia, Jordi Gordillo, Marta M. Bosca, Javier P. Gisbert, M. Barreiro-de-Acosta, M Aguas, Rufo Lorente, Ignacio Marín-Jiménez, M Navarro-Llavat, M. Van Domselaar, A Gutiérrez Casbas, Míriam Mañosa, V Laredo, E. Sierra, J.L. Pérez-Calle, Isabel Vera-Mendoza, David Olivares, M Vela, L de Castro, L Madero, M. Rivero, E. Domènech, María Dolores Martín-Arranz, Raquel Muñoz, Victor J. Morales, M González-Vivó, Elena Ricart, Xavier Calvet, E. Iglesias, E Sánchez-Rodríguez, C Rodríguez, Fernando Bermejo, Rubén Francés, C Muñoz-Villafranca
Publikováno v:
Journal of Crohn's and Colitis. 15:S567-S568
Background Previous studies comparing inflammatory bowel disease(IBD) features between migrant and native patients have shown clinical phenotype differences. To date, no study has focused on IBD immigrants(MP) in Spain. The aim of this study was to e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3404f2bd025d8a4d2b5be1c0d7d2106a
https://doi.org/10.1093/ecco-jcc/jjab076.750
https://doi.org/10.1093/ecco-jcc/jjab076.750
Autor:
U Aresti Goiriena, M Irigoyen Muñoz, Á J Calderón García, C Muñoz-Villafranca, N A Rivera Garcia, J Ortiz de Zárate, P. Arreba González, N Ispizua
Publikováno v:
Journal of Crohn's and Colitis. 15:S148-S149
Background Currently,endoscopy,an invasive medical procedure, is the gold standard for diagnosis of inflammatory bowel disease (IBD) and to determine mucosal activity.Our main goal was to identify biomarkers in saliva samples that can be used as a sc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4064b299d189223a7d6c3c07c0611f4b
https://doi.org/10.1093/ecco-jcc/jjab076.164
https://doi.org/10.1093/ecco-jcc/jjab076.164
Autor:
M L Garcia-Vivar, M Irigoyen, A Bilbao, Gastro-Reuma, Nerea Hernandez-Aretxabaleta, C Garcia-Gomez, J Ortiz de Zárate, C Muñoz-Villafranca, Paz Arreba, U Aresti, Martin Irabien
Publikováno v:
Journal of Crohn's and Colitis. 15:S281-S282
Background Drug-induced lupus (DIL) has been described as an adverse event of an immunological nature, in relation to treatment with anti-TNFα drugs. It is considered as a manifestation uncommon in patients with inflammatory bowel disease (IBD). The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d36c3966646e47a78619a350ae052d95
https://doi.org/10.1093/ecco-jcc/jjab076.360
https://doi.org/10.1093/ecco-jcc/jjab076.360